Industry

RIYADH, Kingdom of Saudi Arabia–(BUSINESS WIRE)–#genomics–King Faisal Specialist Hospital and Research Centre (KFSH&RC) will integrate Saphetor’s proprietary human genome variant interpretation engine, VarSome, into its research and clinical genomics programs. The integration aligns with Saudi Arabia’s Vision 2030 to strengthen the Kingdom’s healthcare sector and its services with technological advancements. KFSH&RC is a leading tertiary … [Read more…]

Company Also Appoints Seasoned Industry Executive, Dr. Angelos Stergiou, as Board of Directors Chairman in Advance of Lead Program Entering the Clinic UTRECHT, Netherlands–(BUSINESS WIRE)–CLEARA Biotech B.V. (“Cleara” or the “Company”), a preclinical-stage biotechnology company focused on developing innovative, proprietary therapies for treating different pathologies of “scarred cellular” senescence, including late-stage cancer and chronic diseases, … [Read more…]

Replacing Makis Kosmatos, Raghu Krishnan will spearhead all areas of Johnson & Johnson’s Consumer health strategic development across the area DUBAI–(BUSINESS WIRE)–Johnson & Johnson Consumer Health, are pleased to announce the appointment of Raghu Krishnan as the new Area Managing Director for AMET (Africa, Middle East, and Turkey), effective September 1st, 2022. Raghu Krishnan is … [Read more…]

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), pursuant to which Highbridge has committed to provide a … [Read more…]

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds … [Read more…]

BEIJING–(BUSINESS WIRE)–#ADC–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite®-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform Progress of Project … [Read more…]

Work begins on modern inpatient behavioral health treatment and education facility in Metro Detroit, slated to open in 2024 WEST BLOOMFIELD, Mich.–(BUSINESS WIRE)–Henry Ford Health, one of the nation’s premier academic and integrated health systems, and Acadia Healthcare, the nation’s largest stand-alone behavioral healthcare company, broke ground today on a state-of-the-art behavioral health treatment and … [Read more…]

Approval also marks the second NGS-based companion diagnostic to identify RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC) CARLSBAD, Calif.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive … [Read more…]

Career healthcare finance executive brings extensive experience to Kyros, a first of its kind digital platform for recovery services, as first C-suite hire. MINNEAPOLIS–(BUSINESS WIRE)–Kyros, the nation’s first of its kind digital platform for people and organizations within the recovery community, has added Nick Christianson as Chief Financial Officer. Nick is the first C-Suite hire … [Read more…]

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL’s Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022. This is the twenty-first dividend declared by BIOQUAL. Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements … [Read more…]